An open-label extension study of 121 pediatric patients with Tourette syndrome evaluated the safety profile of the investigational drug ecopipam for up to 12-months of treatment.
An open-label extension study of 121 pediatric patients with Tourette syndrome evaluated the safety profile of the investigational drug ecopipam for up to 12-months of treatment.